|Mr. Robert Neville||Co-Founder, Exec. Chairman & CEO||772.75k||995.54k||1966|
|Dr. Jaakko Taneli Jouhikainen||Pres & COO||751.09k||N/A||1966|
|Mr. David L. Lowrance||CFO & Sec.||503.89k||426.1k||1968|
|Ms. Anne Erickson||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Ms. Kate McCabe||VP of Legal Affairs||N/A||N/A||N/A|
Savara Inc. operates as an orphan lung disease company. Its lead product candidate includes Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis; and in Phase IIa development stage for treating nontuberculous mycobacterial lung infection. The company is also developing AeroVanc, an inhaled vancomycin that is in Phase III stage for the treatment of methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis. Savara Inc. is headquartered in Austin, Texas.
Savara Inc.’s ISS Governance QualityScore as of July 29, 2019 is 3. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 1; Compensation: 5.